Berger Montague Launches Class Action Against Tenax Therapeutics on Investor's Behalf

In a significant development for investors, Berger Montague, a prominent law firm specializing in plaintiffs' rights, has initiated a class action lawsuit against Tenax Therapeutics, Inc. (NASDAQ: TENX). The suit pertains to investors who acquired Tenax securities from November 13, 2023, to August 7, 2026, a period marked by allegations of misleading statements by the company's executives regarding its lead drug candidate, TNX-103.

The Basis of the Lawsuit


The complaint was filed in the United States District Court for the Middle District of North Carolina, under Case No. 26-cv-01624. The lawsuit highlights violations of Sections 10(b) and 20(a) of the Securities Exchange Act of 1934, as well as Rule 10b-5. According to the allegations, Tenax's executives not only overstated the potential of TNX-103 in treating pulmonary hypertension but also described its development as being inherently “derisked.” This claim was based on previous approvals of levosimendan and encouraging results from the Phase 2 HELP study, which indicated improvements in patients’ physical endurance.

However, the complaint asserts that the reality was far less favorable. The executives reportedly failed to disclose the drug’s true efficacy and the substantial risks surrounding its clinical development.

Emerging Truth


The disillusionment began on August 10, 2026, when Tenax revealed pivotal results from its Phase 3 LEVEL trial. The company acknowledged that TNX-103 did not meet its primary endpoint of improvement in six-minute walk distance when compared to placebo, nor did it show improvement in secondary endpoints such as the Kansas City Cardiomyopathy Questionnaire total symptom score. Following this announcement, Tenax's stock plummeted approximately 89.77%, illustrating the market's reaction to the disappointing data.

What Investors Should Do


For investors who purchased Tenax securities during the class action period, the firm has set a deadline of December 28, 2026, to apply for lead plaintiff status in this lawsuit. To pursue this action or seek additional information, affected investors are encouraged to reach out to Berger Montague. Attorneys Andrew Abramowitz and Caitlin Adorni can be contacted directly via email for further assistance.

About Tenax Therapeutics


Headquartered in Chapel Hill, North Carolina, Tenax Therapeutics focuses on innovative therapies aimed at treating cardiopulmonary conditions. Its lead drug candidate, levosimendan, was under examination in the LEVEL study, with aspirations of transforming the treatment landscape for patients experiencing heart failure with preserved ejection fraction.

Berger Montague's Role


Berger Montague is recognized nationally for its role in complex civil litigation and class action lawsuits, boasting a significant track record, including securing over $50 billion for its clients. The firm continues to advocate fiercely for investors' rights, contributing meaningfully to holding corporations accountable for their actions. For over 55 years, Berger Montague has remained a key player in developing legal frameworks to protect investor interests.

With growing concerns about corporate transparency and accountability, this lawsuit marks an essential step for investors seeking clarity and justice following potentially misleading corporate practices.

  • ---
For detailed inquiries and potential representation, investors should contact Berger Montague.


Topics Other)

【About Using Articles】

You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.

【About Links】

Links are free to use.